ReviewPLoS pathogens2025
The metabolic, microbial and immunological demands of pneumococcal colonisation.
Review in PLoS pathogens, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Antimicrobial Resistance and Genomic Characterization of a Novel ST181Antibiotics (Basel, Switzerland) · 2026Article
- Article
- Bacterial and host factors affecting acquisition ofInfection and immunity · 2026Article
- Immune pathways that regulate neutrophil activation and replenishment prevent persistent pneumococcal colonization.PLoS pathogens · 2026Article
- Future Pneumococcal Vaccines: Shifting from Capsular Polysaccharides to Protein-Based Immunogens.Vaccines · 2026Review
- Immune pathways that regulate neutrophil activation and replenishment prevent persistent pneumococcal colonization.bioRxiv : the preprint server for biology · 2026Article
- Bacterial and host factors affecting acquisition ofbioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Streptococcus pneumoniae (the pneumococcus) causes a range of life-threatening diseases including pneumonia, sepsis and meningitis. Despite widespread vaccine deployment, pneumococcal disease remains a leading cause of global mortality. The human nasopharynx is its principal ecological niche, and all pneumococcal disease originates from this reservoir of organisms. Acute infections are, however, an evolutionary dead-end for the pneumococcus. What sustains the pneumococcus within human populations are cycles of colonisation and transmission. To persist within the nasopharynx, it must overcome the physical and immunological barriers established by the host while acquiring sufficient nutrients to proliferate in the face of competing airway microbes. Here, we outline the metabolic, microbial, and immunological challenges of colonisation, and the often-competing demands of transmission, which together have shaped the pneumococcus into one of the most formidable human pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.